An observational study in Thyroid Disease, Parathyroid Disease and Endocrine Gland, sponsored by University of Arkansas. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-31.
Sponsored by University of Arkansas · Observational
The goal of this study is to help better determine the complication rates for endocrine surgery across the nation for both benign and malignant disease. It is our hypothesis that the complication rates are low overall and that malignant disease results in a higher complication rate than benign disease. This study will do a database review from all University HealthSystem Consortium (UHC).
967 studies on the registry are indexed under Thyroid Diseases; 197 are open to participants now.
This study's enrollment of 1,000 is above the median of 150 across 381 observational studies indexed under Thyroid Diseases.
Browse Thyroid Diseases studies →University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study will be conducted through a United HealthSystem Consortium query of endocrine surgery done as a primary procedure for specific diagnosis.
Exclusion Criteria:
Complication Rates for Endocrine Surgery
The information presented in this report will provide a surgical tool for otolaryngologists to safely inform patients on the risks of endocrine surgery.
Time frame: baseline
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Arkansas